Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 29, 2022

Survival Outcomes of an Irinotecan, Temozolomide, Dinutuximab, GM-CSF Regimen in Patients With Relapsed High-Risk Neuroblastoma

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor
J. Clin. Oncol 2022 Oct 07;[EPub Ahead of Print], BJ Lerman, Y Li, C Carlowicz, M Granger, T Cash, A Sadanand, K Somers, A Ranavaya, BD Weiss, M Choe, JH Foster, N Pinto, DA Morgenstern, MS Rafael, KA Streby, RN Zeno, R Mody, S Yazdani, AV Desai, ME Macy, S Shusterman, SM Federico, R Bagatell

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.


Further Reading